The North America TB diagnostics market size was valued at USD 540.00 million in 2025 and is projected to reach USD 569.59 million in 2026 and USD 872.82 million by 2034, growing at a CAGR of 5.48% during the forecast period 2026-2034.
Tuberculosis (TB) is an infectious illness caused by Mycobacterium tuberculosis bacteria (MTB). Tuberculosis is most associated with the lungs, although it may also affect other regions of the body. Most infections are asymptomatic, which is known as latent TB. Roughly 10% of latent infections proceed to active illness, which kills about half of individuals afflicted if left untreated. A persistent cough with bloody sputum, fever, night sweats, and weight loss are all hallmark indications of active tuberculosis. Weight loss gave rise to the historical phrase "consumption." Other organ infections can generate a variety of symptoms.
The bacterium Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.
One of the primary drivers driving market growth is the high prevalence of TB in the region, as well as favourable health-care policies. According to the World Economic Forum, North America has a robust economy, accounting for 27.95% of global GDP, which is one of the elements influencing the healthcare sector. When comparing the two countries, the US spends more on healthcare than Canada. Additionally, the industry is being driven by greater rise in expenditure for private hospital care, physician, health insurance, and clinical services. Furthermore, the need for TB diagnosis tools and medicines is reflected in healthcare and public spending, which serves as a key driver for this market. Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent TB diagnostic procedure is a skin test; however, blood tests are becoming more widespread.
Download a Free Sample To learn more about this report,
Multiplex Molecular TB Assays
The North America TB Diagnostics Market analysis shows that multiplex molecular TB assays are gaining relevance as diagnostic programs seek to detect TB and multiple drug-resistance markers from the same clinical sample. The transition toward broader molecular panels allows laboratories to obtain more diagnostic information in a single test, while WHO’s 2025 diagnostic guidance includes automated NAAT technologies that support simultaneous TB detection and resistance testing. This shift supports faster diagnostic decisions and more efficient molecular testing workflows across North America.
Genomic Detection of Emerging Drug Resistance
Genomic detection of drug resistance is becoming more important as laboratories need to identify resistance mutations before conventional culture-based testing is complete. The transition toward targeted next-generation sequencing allows detection of resistance-associated mutations across multiple drugs, with the CDC’s MDDR tNGS assay examining 24 amplicons across 16 genes and providing information on more than 12 antituberculosis drugs. This approach supports earlier treatment selection and strengthens genomic surveillance of drug-resistant TB in North America.
Integration of TB Testing into Routine Healthcare Services and Public Health Investment in TB Detection Drive Market
Integration of TB testing into primary care, hospitals, and other routine healthcare settings expands the number of patients who can access diagnostic services. Routine screening protocols create steady demand for TB tests among patients with symptoms, exposure risks, or relevant travel and immigration histories. This demand supports wider availability of laboratory-based and rapid diagnostic products across healthcare facilities. For example, healthcare providers can include TB screening within pre-employment, immigration, or pre-treatment evaluations where TB assessment is required. Broader integration of testing into routine services therefore supports sustained demand for TB diagnostics across North America.
Public health funding for TB surveillance, screening, laboratory capacity, and case detection creates demand for diagnostic products and services. Government-supported TB programs require reliable testing capacity to identify cases and monitor populations at higher risk of infection. Such investment also supports the procurement of diagnostic kits, laboratory equipment, and testing services by public health departments. For example, U.S. and Canadian public health programs use targeted TB screening and laboratory testing to support case identification and disease-control activities. Continued investment in detection infrastructure supports demand for TB diagnostic technologies across the region.
Shortage of Skilled Laboratory Professionals and Complexity of Multidrug-Resistant TB Detection Restrain Market Expansion
A shortage of skilled laboratory professionals limits the capacity of healthcare facilities to conduct, interpret, and manage specialized TB diagnostic tests. Limited expertise can increase testing delays and reduce the efficient use of advanced molecular and drug-resistance diagnostic systems. This workforce constraint can restrict diagnostic capacity and slow adoption of advanced TB testing technologies.
The complexity of multidrug-resistant TB detection requires specialized testing methods, laboratory expertise, and additional time to identify resistance patterns accurately. These requirements can increase testing costs and create delays in confirming appropriate treatment options. This diagnostic complexity can limit access to rapid resistance testing and slow broader adoption of advanced TB diagnostic solutions.
Non-Sputum-Based TB Diagnostic Technologies and Rapid Drug Susceptibility Testing for TB Offers Growth Opportunities
Low TB Testing Priority in Routine Healthcare and Complex Laboratory Infrastructure Requirements Hinders Growth
TB can receive less attention among clinicians and healthcare providers as overall incidence remains relatively low, reducing routine demand for diagnostic testing.This limits testing volumes and makes it harder for diagnostic companies to expand beyond specialized TB programs. CDC notes that some providers serving high-risk populations may not prioritize TB testing.
Advanced TB diagnostics still require specialized laboratory workflows, biosafety measures, quality controls, and trained personnel, particularly for culture and drug-susceptibility testing. These requirements increase implementation complexity and can slow adoption across smaller or lower-capacity laboratories.
Nucleic Acid Testing (NAT) is a key diagnostic approach because it rapidly detects Mycobacterium tuberculosis and can also support early identification of drug resistance.The Skin Test / Mantoux Test remains widely used for identifying TB infection, particularly in screening and targeted testing programs. Blood-based TB testing supports infection screening by measuring the immune response to TB-related antigens.Smear microscopy provides a relatively quick method for examining respiratory specimens and identifying acid-fast bacilli during TB evaluation.Culture-based testing remains an important laboratory method because it provides confirmation of TB disease and supports drug susceptibility testing.Radiography tests support TB diagnosis by identifying abnormalities in the lungs that may indicate active pulmonary disease. Other diagnostic methods complement established testing approaches in cases requiring additional clinical or laboratory evaluation.
Request Customizationto receive a tailored report.
Hospitals and diagnostic laboratories represent important end users because they provide comprehensive TB testing and manage patients requiring diagnostic confirmation and treatment decisions. Physician’s office laboratories support initial TB screening and diagnostic evaluation by providing testing closer to routine patient care settings. Reference laboratories handle specialized and complex TB testing, including molecular and confirmatory laboratory procedures that may not be available in smaller facilities.Academic and research facilities support the development and evaluation of new TB diagnostic technologies, testing methods, and drug-resistance detection approaches.
Speak to an Analystto discuss market opportunities.
The CDC has set a 2030 target of reducing TB incidence in the U.S. to 1.48 cases per 100,000 population, alongside targets for improved case management and laboratory reporting, supporting continued demand for TB diagnostic testing.The Government of Canada aims to eliminate TB among Inuit across Inuit Nunangat by 2030 and reach a pre-elimination incidence of less than 10 notified cases per million population across Canada by 2035, requiring continued screening, detection, and diagnostic efforts.
The North America TB Diagnostics Market is moderately fragmented, with the market ecosystem comprising global diagnostic manufacturers, molecular testing companies, laboratory equipment providers, specialized tuberculosis diagnostic firms, clinical laboratories, public health laboratories, biotechnology companies, and regional diagnostic suppliers.
Established players compete mainly through diagnostic accuracy, sensitivity and specificity, regulatory approvals, clinical validation, product reliability, testing speed, broad diagnostic portfolios, laboratory integration, and distribution networks, while the market ecosystem includes emerging players that compete through rapid molecular testing, drug-resistance detection, multiplex assays, portable solutions, automation, cost efficiency, and innovative specimen-based testing technologies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com